MD Anderson shares latest research breakthroughs
Peer-Reviewed Publication
Updates every hour. Last Updated: 6-Nov-2025 17:11 ET (6-Nov-2025 22:11 GMT/UTC)
Bacteria in tumors can drive treatment resistance in cancer
Novel markers can predict improved treatment responses
Studies provide insights into optimal approaches for end-of-life care, ALL
Research improves understanding of neuronal differentiation, precancerous tissue
Researchers at Rice University, UTHealth School of Dentistry, and The University of Texas M.D. Anderson Cancer Center have developed a smartphone-based imaging system, mDOC, to help dental professionals identify patients who may need referral for oral cancer evaluation. The device captures white light and autofluorescence images of the mouth and uses a machine learning algorithm to assess risk. In a study of 50 patients at community dental clinics, the system demonstrated 60 percent sensitivity and 88 percent specificity in identifying lesions requiring expert review—outperforming standard clinical exams. The technology offers a fast, low-cost tool to support early detection and timely referral in routine dental care settings.
Healing doesn’t end with treatment. As cancer survivorship grows, many continue to struggle with anxiety and depression – often in silence. A new review highlights how caring-healing modalities (CHMs) like mindfulness and peer support can build resilience and reduce emotional distress. These human-centered approaches shift focus from treatment to healing, helping survivors reclaim their sense of self. Rooted in empathy and emotional expression, CHMs offer a whole-person approach that meets the deep psychological needs often overlooked in survivorship care –especially among breast cancer survivors.
The Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology in Stuttgart has developed a pioneering therapeutic approach for breast cancer patients who respond poorly to the standard drug tamoxifen. The innovative combination therapy has been successfully tested in a clinical trial under the name TAMENDOX. The results have now been published in the renowned journal Clinical Cancer Research. The project was funded by the German Federal Ministry of Research, Technology, and Space.
The study, published in the journal Oncogene, shows how a specific molecular interaction determines the effectiveness of irinotecan in this type of paediatric cancer